| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
Inhibiting cell growth and causing cell cycle arrest in the G2/M phase, ciprofloxacin (Bay-09867) monoHClide (5-50 μg/mL; 0-24 hours; tenocytes) is used to treat infections [1]. Yersinia pestis and Bacillus anthracis are effectively inhibited by ciprofloxacin (Bay-09867) monoHClide, demonstrating MIC90 values of 0.03 μg/mL and 0.12 μg/mL, respectively [2].
|
|---|---|
| ln Vivo |
In a mouse model of pneumonic plague, ciprofloxacin (Bay-09867) monohydrochloride (30 mg/kg; i.p.; 24 hours; BALB/c mice) is protective against Y. pestis [3]. By decreasing LOX levels and raising MMP levels and activity, ciprofloxacin (Bay-09867) monohydrochloride (100 mg/kg; ir; daily for 4 weeks; C57BL/6J mice) accelerates aortic root expansion and raises the risk of aortic dissection and rupture of the aorta wall [4]. Ciprofloxacin (Bay-09867) monoHClide (100 mg/kg; ir; daily for 4 weeks; C57BL/6J mice) causes mitochondrial dysfunction, activation of cytoplasmic DNA sensor signaling, and DNA damage and release into the cytoplasm. Apoptosis and necroptosis in the aorta wall are increased by ciprofloxacin lactate [4].
|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: Tenocytes Tested Concentrations: 5, 10, 20 and 50 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: diminished cellularity of tenocytes. Cell cycle analysis [1] Cell Types: Tenocytes Tested Concentrations: 50 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: The cell cycle was arrested in the G2/M phase and inhibited cell division of tenocytes. Western Blot Analysis [1] Cell Types: tenocytes Tested Concentrations: 50 μg/mL Incubation Duration: 0, 6, 12, 17 and 24 hrs (hours) Experimental Results: Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Upregulates the expression of PLK-1 protein. |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse [3]
Doses: 30 mg/kg Route of Administration: intraperitoneal (ip) injection; 24-hour Experimental Results: diminished the bacterial load in the lungs of the plague mouse model. Animal/Disease Models: C57BL/6J mice [4] Doses: 100 mg/kg Route of Administration: po (oral gavage); one time/day for 4 weeks Experimental Results: The aorta was destroyed, accompanied by diminished LOX expression and MMP expression and activity Increase. Animal/Disease Models: C57BL/6J mice [4] Doses: 100 mg/kg Route of Administration: po (oral gavage); one time/day for 4 weeks Experimental Results: Causes mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased aortic wall cell apoptosis and necroptosis. |
| References |
[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.
[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16. [3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91. [4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. |
| Molecular Formula |
C17H19CLFN3O3
|
|---|---|
| Molecular Weight |
367.8025
|
| CAS # |
93107-08-5
|
| Related CAS # |
Ciprofloxacin;85721-33-1;Ciprofloxacin hydrochloride monohydrate;86393-32-0;Ciprofloxacin-d8 hydrochloride hydrate
|
| SMILES |
Cl[H].FC1C([H])=C2C(C(C(=O)O[H])=C([H])N(C2=C([H])C=1N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])C1([H])C([H])([H])C1([H])[H])=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~12.5 mg/mL (~33.99 mM)
DMSO : ~5 mg/mL (~13.59 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7189 mL | 13.5943 mL | 27.1887 mL | |
| 5 mM | 0.5438 mL | 2.7189 mL | 5.4377 mL | |
| 10 mM | 0.2719 mL | 1.3594 mL | 2.7189 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
